News

Abstract
27 April—(icanNEWS) A US Food and Drug Administration (FDA) committee yesterday gave a mixed endorsement to telithromycin, the first of the ketolide family of antibiotics, recommending its approval as a first-line treatment for community-acquired pneumonia (CAP) but not accepting claims that it is a new weapon for treating penicillin- and erythromycin-resistant pneumonia.
Keywords

This publication has 0 references indexed in Scilit: